Cargando…
Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation
PURPOSE: SARS-CoV-2 infection may cause varying degrees of cardiac injury and the presence of underlying cardiovascular morbidities contributes to the frequency and severity of occurrence of this complication. Lipodystrophy syndromes are frequently characterized by severe metabolic derangements that...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984660/ https://www.ncbi.nlm.nih.gov/pubmed/35384599 http://dx.doi.org/10.1007/s40618-022-01795-6 |
_version_ | 1784682237855268864 |
---|---|
author | Ceccarini, G. Gilio, D. Magno, S. Pelosini, C. Leverone, M. Miceli, C. Barison, A. Fabiani, I. Emdin, M. Santini, F. |
author_facet | Ceccarini, G. Gilio, D. Magno, S. Pelosini, C. Leverone, M. Miceli, C. Barison, A. Fabiani, I. Emdin, M. Santini, F. |
author_sort | Ceccarini, G. |
collection | PubMed |
description | PURPOSE: SARS-CoV-2 infection may cause varying degrees of cardiac injury and the presence of underlying cardiovascular morbidities contributes to the frequency and severity of occurrence of this complication. Lipodystrophy syndromes are frequently characterized by severe metabolic derangements that represent relevant cardiovascular risk factors. Besides causing lipodystrophy, mutations in the lamin A/C (LMNA) gene can lead to a wide spectrum of tissue-specific disorders including cardiac involvement. METHODS AND RESULTS: We herein examine the case of two patients affected by atypical progeroid syndrome and partial lipodystrophy due to a heterozygous missense LMNA mutation c.1045 C > T (p.R349W) who presented initially with mild COVID-19 and developed severe cardiovascular complications within few weeks of SARS-CoV-2 infection. Before being infected with SARS-CoV-2, our patients had cardiovascular morbidities (mild mitral regurgitation in one patient, ischemic heart disease with bifascicular block in the other patient) in adjunct to cardiovascular risk factors, but the SARS-CoV-2 infection contributed to quickly and significantly decompensate their balance. CONCLUSION: These findings warn that patients affected by LMNA p.R349W mutation and likely other LMNA mutations associated with cardiovascular morbidity should be considered at extremely elevated risk of post-acute cardiological manifestations and should therefore undergo a vigilant follow-up after SARS-CoV-2 infection. Both patients developed COVID-19 before the specific vaccination was available to them and this unfortunate situation should remark the importance of vaccination coverage against SARS-CoV-2 infection for all patients affected by lipodystrophy, especially those with underlying comorbidities. |
format | Online Article Text |
id | pubmed-8984660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-89846602022-04-06 Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation Ceccarini, G. Gilio, D. Magno, S. Pelosini, C. Leverone, M. Miceli, C. Barison, A. Fabiani, I. Emdin, M. Santini, F. J Endocrinol Invest Original Article PURPOSE: SARS-CoV-2 infection may cause varying degrees of cardiac injury and the presence of underlying cardiovascular morbidities contributes to the frequency and severity of occurrence of this complication. Lipodystrophy syndromes are frequently characterized by severe metabolic derangements that represent relevant cardiovascular risk factors. Besides causing lipodystrophy, mutations in the lamin A/C (LMNA) gene can lead to a wide spectrum of tissue-specific disorders including cardiac involvement. METHODS AND RESULTS: We herein examine the case of two patients affected by atypical progeroid syndrome and partial lipodystrophy due to a heterozygous missense LMNA mutation c.1045 C > T (p.R349W) who presented initially with mild COVID-19 and developed severe cardiovascular complications within few weeks of SARS-CoV-2 infection. Before being infected with SARS-CoV-2, our patients had cardiovascular morbidities (mild mitral regurgitation in one patient, ischemic heart disease with bifascicular block in the other patient) in adjunct to cardiovascular risk factors, but the SARS-CoV-2 infection contributed to quickly and significantly decompensate their balance. CONCLUSION: These findings warn that patients affected by LMNA p.R349W mutation and likely other LMNA mutations associated with cardiovascular morbidity should be considered at extremely elevated risk of post-acute cardiological manifestations and should therefore undergo a vigilant follow-up after SARS-CoV-2 infection. Both patients developed COVID-19 before the specific vaccination was available to them and this unfortunate situation should remark the importance of vaccination coverage against SARS-CoV-2 infection for all patients affected by lipodystrophy, especially those with underlying comorbidities. Springer International Publishing 2022-04-06 2022 /pmc/articles/PMC8984660/ /pubmed/35384599 http://dx.doi.org/10.1007/s40618-022-01795-6 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Ceccarini, G. Gilio, D. Magno, S. Pelosini, C. Leverone, M. Miceli, C. Barison, A. Fabiani, I. Emdin, M. Santini, F. Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation |
title | Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation |
title_full | Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation |
title_fullStr | Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation |
title_full_unstemmed | Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation |
title_short | Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation |
title_sort | post-acute cardiac complications following sars-cov-2 infection in partial lipodystrophy due to lmna gene p.r349w mutation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984660/ https://www.ncbi.nlm.nih.gov/pubmed/35384599 http://dx.doi.org/10.1007/s40618-022-01795-6 |
work_keys_str_mv | AT ceccarinig postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation AT giliod postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation AT magnos postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation AT pelosinic postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation AT leveronem postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation AT micelic postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation AT barisona postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation AT fabianii postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation AT emdinm postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation AT santinif postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation |